eplerenone的用法用量

It is a new generation of selective aldosterone antagonist, developed by Pfizer, and first launched in the United States in 2002 under the trade name Inspra. Eplerenone is indicated for the treatment of congestive heart failure after acute myocardial infarction and is also used to treat hypertension. Eplerenone is a good medicine for the treatment of hypertension, and can also be used as a medicine for myocardial ischemia and chronic myocardial insufficiency. It can protect the liver, heart disease, and kidneys without damaging the organs, and can promote urination without losing potassium.

  The recommended dose of eplerenone for the treatment of adults with congestive heart failure is: initial dose: 25 mg orally, once daily; gradually increase to target dose within 4 weeks as tolerated by the patient. Target dose: 50 mg orally once daily.

Common dosages for the treatment of hypertension in adults: eplerenone can be used alone or in combination with other antihypertensive drugs. Initial dose: 50 mg orally once daily; Maintenance dose: 50 mg orally once or twice daily; Maximum dose: 100 mg/day. Obvious antihypertensive effects appear within four weeks of taking the drug. Patients whose blood pressure responds inadequately to the initial dose may be increased to 50 mg twice daily.

In addition, you should pay attention to the following when taking eplerenone:

1. Liver damage: Use with caution in patients with moderate to severe liver damage.

2. Kidney damage: As kidney function declines, the risk of hyperkalemia increases. Use with caution in patients with mild renal impairment; it may be disabled depending on the indications and degree of damage.

3. Drug-Drug Interactions: Significant interactions may exist requiring dose or frequency adjustment, additional monitoring, and/or the selection of alternative therapies.

4. Potassium supplements: Avoid potassium supplements, potassium-containing salt substitutes, potassium-rich diets, or other drugs that may cause hyperkalemia (such as other potassium-sparing diuretics, nonsteroidal anti-inflammatory drugs). Concomitant use of potassium supplements or potassium-sparing diuretics is contraindicated in the treatment of hypertension.

5. Pregnancy: Untreated high blood pressure and heart failure are both associated with adverse pregnancy outcomes. The use of mineralocorticoid receptor antagonists is not recommended for the treatment of chronic isolated hypertension in pregnant women and should generally be avoided in women of reproductive potential.